Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04789668 · ClinicalTrials.gov registry record · Phase 1
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04789668: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT04789668 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04789668, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases). Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of the monoclonal antibody anti-PD-L1 and TGF-beta, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pimasertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pimasertib and bintrafusp alfa may help to prevent or delay the cancer from progressing (getting worse) and/or coming back.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Bintrafusp Alfa
- DRUG Pimasertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04789668
The ClinicalTrials.gov registry entry for NCT04789668 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04789668 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04789668 about?
NCT04789668 is a clinical study titled "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases". This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases). Immunotherapy with bintrafusp alfa, a bifunctional fusion protein composed of the monoclonal antibody anti-PD-L1 ...
What is the current status of trial NCT04789668?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-01-15. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT04789668?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Bintrafusp Alfa (DRUG), Pimasertib (DRUG).
Who is sponsoring clinical trial NCT04789668?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.